Product Candidates

We are leveraging our technology platform, initiatives and collaborations to discover new biomarkers for clinically and commercially important diseases and treatments. From these biomarker discoveries, we aim to create a broad and robust pipeline of molecular diagnostic products with high potential value to improve patient outcomes and contain healthcare costs. Our molecular diagnostic tests are designed to predict a patient’s response to a drug therapy, determine the potential toxicity of therapeutic agents to patients, identify patients who have or are likely to develop a specific disease, predict a patient’s prognosis once a disease has been diagnosed, or monitor a patient’s disease progression or drug response. Our product pipeline includes molecular diagnostics for cardiovascular disease, cancer, CNS disorders and other diseases.